2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

9:00AM-11:00AM: Abstract Number: 704

Detection of dsDNA Antibodies By New Fluoroimmunoassay with Comparable Diagnostic Sensitivity and Specificity to Farr-Ria

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 587

Detection of Structural Lesions on T1 Weighted MRI Versus Radiography of the Sacroiliac Joints in Early Axial Spa: 2-Year Data

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 357

Determinants of Patient and Physician Disagreement on Presence of a Gout Flare

Patient Outcomes, Preferences, and Attitudes Poster I

9:00AM-11:00AM: Abstract Number: 90

Developing a Pediatric Rheumatology Curriculum for Pediatric Residents

Education Poster

9:00AM-11:00AM: Abstract Number: 246

Development and Validation of a Flourescence Optical Imaging Rheumatoid Arthritis Scoring System for Synovitis in the Wrist and Hand

Imaging of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 695

Development of a Multimarker Model for the Detection of Systemic Lupus Erythematosus Based on New and Traditional Autoantibodies

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 91

Development of Musculoskeletal Physical Examination Checklists: A Formal Consensus Project Involving National Educators

Education Poster

9:00AM-11:00AM: Abstract Number: 581

Diagnostic Value of Anti-CD74 Antibodies in Early Axial Spondyloarthritis: Data from the Spondyloarthritis Caught Early (SPACE) Cohort

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I

9:00AM-11:00AM: Abstract Number: 127

Diet Change and Omega-3 Supplementation in the First Three Years Following a Diagnosis with Rheumatoid Arthritis in Sweden

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 777

Differences between Temporal Artery Biopsy-Positive and Biopsy-Negative Giant Cell Arteritis: A Comparative Cohort Study

Vasculitis Poster I: Large Vessel Vasculitis

9:00AM-11:00AM: Abstract Number: 485

Different Citrullination Profiles in Spontaneous Versus Leukemia-Associated Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 722

Differential Diagnosis of Autoimmune Diseases, Outlier Detection Plus Subgrouping in Clinical Trials By High Content Autoantibody Profiling

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 167

Differentially Co-Expressed Gene Networks in Previously DMARD-Naïve Patients with Early RA Achieving Sustained Drug-Free Remission after Step-up Methotrexate Therapy

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 750

Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 281

Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Virus Infection in France

Infection-related Rheumatic Disease Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].